Related Experiment Video

Updated: Jun 21, 2026

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

Targeting IGF-1R in the treatment of sarcomas: past, present and future

Su Young Kim1, Xiaolin Wan, Lee J Helman

  • 1Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. kimsuyou@mail.nih.gov

Bulletin Du Cancer
|July 21, 2009
PubMed

Insights

Targeting insulin-like growth factor receptor 1 (IGF-1R) with new antibodies shows promise for treating recurrent and refractory sarcomas. These advancements offer hope where traditional therapies have failed, improving patient survival rates.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Multimodality therapy has improved sarcoma cure rates, but metastatic or recurrent disease survival remains poor.
  • The insulin-like growth factor (IGF) family is implicated in tumor development.
  • Recent development of humanized and fully human antibodies targeting IGF-1R offers new therapeutic avenues.

Purpose of the Study:

  • To review preclinical findings, current clinical trials, and future research opportunities for IGF-1R inhibitors in sarcoma treatment.
  • To highlight the potential of targeting the IGF-1R pathway in overcoming therapeutic resistance in sarcomas.

Main Methods:

  • Review of preclinical studies on IGF-1R targeting agents.
  • Analysis of data from ongoing and completed clinical trials involving IGF-1R antibodies in sarcoma patients.
  • Discussion of emerging research directions and potential therapeutic strategies.

Main Results:

  • Preclinical data support the role of IGF-1R in sarcoma tumorigenesis and progression.
  • Clinical trials have demonstrated dramatic responses in some patients with recurrent and refractory sarcomas treated with IGF-1R antibodies.
  • Significant research opportunities exist for optimizing IGF-1R-targeted therapies.

Conclusions:

  • Antibodies targeting IGF-1R represent a promising therapeutic strategy for advanced sarcomas.
  • Further research is crucial to fully elucidate the efficacy and optimal application of IGF-1R inhibitors in sarcoma treatment.
  • Targeting the IGF-1R pathway holds potential for improving outcomes in patients with limited therapeutic options.

More Related Videos

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.